Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Go back to Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
(NASDAQ: BNGO) Delayed: 1.84 +0.11 (6.36%)
Previous Close $1.73    52 Week High
Open $1.73    52 Week Low
Day High $1.89    P/E N/A 
Day Low $1.73    EPS
Volume 886,120